Cantargia saw no growth in patent filings and highest growth of 0.99% in grants in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw no growth in patent filings and grants by 0.99%. GlobalData’s DataBook provides a comprehensive analysis of Cantargia’s patent filings and grants. Buy the databook here.
Smarter leaders trust GlobalData
Cantargia has been focused on protecting inventions in European Patent Office(EPO) with one publication in Q2 2024
The European Patent Office(EPO) Patent Office dominates the patent grants with nearly 100% of grants. The European Patent Office(EPO) patent Office are among the top ten patent offices where Cantargia is filings its patents. Among the top granted patent authorities, Cantargia has 100% of its grants in European Patent Office(EPO).
Regeneron Pharmaceuticals and Roche could be the strongest competitors for Cantargia
Breast cancer related patents lead Cantargia portfolio followed by myasthenia gravis, and rheumatoid arthritis
Cantargia has highest number of patents in breast cancer followed by myasthenia gravis, rheumatoid arthritis, sicca syndrome (sjogren), and systemic sclerosis (scleroderma).
For comprehensive analysis of Cantargia's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData patents database covers bibliographic from all 100+ patenting authorities. All patents are tagged to 18+ industries and 300+ sub-sectors based on technology classification, keywords, and associated companies. They are also tagged to various industries themes (100+) and technology domains (1800+) of focus.
Patents database further disambiguates assignee names (13m names) and associate corporate tree hierarchy in current/point in time ownerships (320k entities). GlobalData sources content directly from national patent offices on a weekly basis.
